Clinical trial accruals at OneOncology increase in the face of COVID-19

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Enrolling patients in clinical trials at OneOncology partner practices has slightly increased in March and April, as the COVID-19 pandemic hit its communities hardest.

OneOncology, a national partnership of independent, community oncology practices, includes five large community oncology practices representing over 400 physicians practicing at more than 160 sites of care in the United States.

“Elective medical procedures have stopped, but caring for cancer patients isn’t elective,” Jeff Patton, OneOncology’s acting CEO and president of Physician Services, said in a statement. “Not only do community oncology centers remain open, providing patients life-saving treatments, we also continue to provide clinical trials at a steady to increased rate. Our centers are continuing to fulfill our collective mission.”

When the Centers for Medicare and Medicaid temporarily loosened its regulations to allow providers to be reimbursed for telehealth visits, the agency allowed researchers to keep some clinical trials open by evaluating and enrolling out-of-state patients.

“By loosening the regulations at both the federal and state levels, we were able to evaluate patients for eligibility in clinical trials that we otherwise couldn’t because of state licensing requirements,” Natalie Dickson, chief medical officer at Tennessee Oncology and chair of OneCouncil, the partnership’s all-physician committee, said in a statement.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login